Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Justification for Recommendation: ADA Obesity Management Recommendation 8.17 - XML Representation

Raw xml | Download

<ArtifactAssessment xmlns="http://hl7.org/fhir">
  <id value="179515"/>
  <meta>
    <versionId value="20"/>
    <lastUpdated value="2025-08-14T16:56:33.257Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-justification"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Title: </b>Justification for Recommendation: ADA Obesity Management Recommendation 8.17</p><br/><p><b>Justification for Recommendation: </b>Recommendation: ADA Obesity Management Recommendation 8.17</p><br/><table><tr><th>Concept</th><th>Summary</th><th>Rating</th></tr><tr><td>Rating System (coded as: rating-system from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>ADA Level of Evidence</td></tr><tr><td>Direction of Recommendation (coded as: direction-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>Favors intervention (coded as: RJCS-2021 from https://fevir.net/resources/CodeSystem/27834)</td></tr><tr><td>Ratings (coded as: ratings from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>A</td></tr><tr><td>Recommendation Rating (coded as: recommendation-rating from https://fevir.net/resources/CodeSystem/179423)</td><td>8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</td><td>undefined</td></tr><tr><td>Evidence (coded as: evidence from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Summary of Findings (coded as: summary-of-findings from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<br/>In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.</td><td>undefined</td></tr><tr><td>Competing Interests (coded as: competing-interests from https://fevir.net/resources/CodeSystem/179423)</td><td>All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</td><td>undefined</td></tr></table><br/></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-description">
    <valueMarkdown
                   value="An example using the ArtifactAssessment Resource for representation of the many judgments and concepts used to justify a recommendation."/>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to">
    <extension url="type">
      <valueCode value="derived-from"/>
    </extension>
    <extension url="targetReference">
      <valueReference>🔗 
        <reference value="Citation/32137"/>
        <type value="Citation"/>
        <display
                 value="GuidelineCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes (32137)"/>
      </valueReference>
    </extension>
  </extension>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="179515"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title
         value="Justification for Recommendation: ADA Obesity Management Recommendation 8.17"/>
  <citeAs
          value="Justification for Recommendation: ADA Obesity Management Recommendation 8.17 [Database Entry: FHIR ArtifactAssessment Resource]. Contributors: In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179515. Revised 2025-08-14. Available at: https://fevir.net/resources/ArtifactAssessment/179515. Computable resource at: https://fevir.net/resources/ArtifactAssessment/179515#json."/>
  <artifactReference>🔗 
    <reference value="Composition/179467"/>
    <type value="Composition"/>
    <display
             value="Recommendation: ADA Obesity Management Recommendation 8.17"/>
  </artifactReference>
  <content>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="rating-system"/>
        <display value="Rating System"/>
      </coding>
    </type>
    <classifier>
      <text value="ADA Level of Evidence"/>
    </classifier>
    <freeToShare value="true"/>
  </content>
  <content>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="strength-of-recommendation"/>
        <display value="Strength of Recommendation"/>
      </coding>
    </type>
    <freeToShare value="true"/>
  </content>
  <content>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="direction-of-recommendation"/>
        <display value="Direction of Recommendation"/>
      </coding>
    </type>
    <classifier>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/27834"/>
        <code value="RJCS-2021"/>
        <display value="Favors intervention"/>
      </coding>
    </classifier>
    <freeToShare value="true"/>
  </content>
  <content>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ratings"/>
        <display value="Ratings"/>
      </coding>
    </type>
    <classifier>
      <text value="A"/>
    </classifier>
    <freeToShare value="true"/>
  </content>
  <content>
    <summary
             value="ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions."/>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="evidence"/>
        <display value="Evidence"/>
      </coding>
    </type>
    <relatesTo>
      <type value="justification"/>
      <targetReference>🔗 
        <reference value="Citation/33089"/>
        <type value="Citation"/>
        <display
                 value="JournalArticleCitation: Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations"/>
      </targetReference>
    </relatesTo>
    <relatesTo>
      <type value="justification"/>
      <targetReference>🔗 
        <reference value="Evidence/33244"/>
        <type value="Evidence"/>
        <display
                 value="ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"/>
      </targetReference>
    </relatesTo>
    <freeToShare value="true"/>
    <component>
      <summary
               value="ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions."/>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="summary-of-findings"/>
          <display value="Summary of Findings"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="desirable-effects"/>
          <display value="Desirable Effects"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="undesirable-effects"/>
          <display value="Undesirable Effects"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <summary
               value="A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.&lt;br/&gt;In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement."/>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="discussion"/>
          <display value="Discussion"/>
        </coding>
      </type>
      <relatesTo>
        <type value="justification"/>
        <targetMarkdown
                        value="Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297–2304"/>
      </relatesTo>
      <relatesTo>
        <type value="justification"/>
        <targetMarkdown
                        value="Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 2019;322:1271–1282"/>
      </relatesTo>
      <relatesTo>
        <type value="justification"/>
        <targetReference>🔗 
          <reference value="Evidence/32144"/>
        </targetReference>
      </relatesTo>
      <freeToShare value="true"/>
    </component>
  </content>
  <content>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="net-effect"/>
        <display value="Net Effect"/>
      </coding>
    </type>
    <freeToShare value="true"/>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="preferences"/>
          <display value="Preferences"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="discussion"/>
          <display value="Discussion"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
  </content>
  <content>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="judgments"/>
        <display value="Judgments"/>
      </coding>
    </type>
    <freeToShare value="true"/>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="justification"/>
          <display value="Justification"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="problem-importance"/>
          <display value="Problem Importance"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="costs"/>
          <display value="Costs"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="cost-effectiveness"/>
          <display value="Cost-effectiveness"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="equity"/>
          <display value="Equity"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="acceptability"/>
          <display value="Acceptability"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
    <component>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="feasibility"/>
          <display value="Feasibility"/>
        </coding>
      </type>
      <freeToShare value="true"/>
    </component>
  </content>
  <content>
    <summary
             value="All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL"/>
    <type>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="competing-interests"/>
        <display value="Competing Interests"/>
      </coding>
    </type>
    <freeToShare value="true"/>
  </content>
</ArtifactAssessment>